Abstract
Objective:
The purpose of this study was to evaluate clinical aspects of recanalization and to assess variables associated with early recanalization.
Methods:
In all, 27 consecutive patients treated with intravenous thrombolysis were examined with the National Institutes of Health Stroke Scale (NIHSS) and transcranial Doppler ultrasound at presentation and at 2 and 24 hours after treatment.
Results:
Recanalization less than 24 hours after treatment was found in 70% of patients. Patients who recanalized had lower NIHSS score on presentation (P = .01) and significant improvement in NIHSS score at 0 to 2 hours (P = .042) and 0 to 24 hours (P = .002) compared with those who did not recanalize. Atrial fibrillation (P = .04), higher serum glucose values on presentation (P = .05), and more traditional risk factors (P = .05) were associated with no recanalization.
Conclusions:
Recanalization is associated with clinical improvement. High NIHSS score, atrial fibrillation, high serum glucose, and higher number of risk factors indicate a reduced probability for recanalization.
MeSH terms
-
Acute Disease
-
Adolescent
-
Adult
-
Aged
-
Aged, 80 and over
-
Atrial Fibrillation / complications
-
Atrial Fibrillation / epidemiology
-
Blood Glucose / analysis
-
Comorbidity
-
Coronary Disease / epidemiology
-
Diabetes Mellitus / blood
-
Diabetes Mellitus / epidemiology
-
Female
-
Fibrinolytic Agents / administration & dosage
-
Fibrinolytic Agents / therapeutic use
-
Humans
-
Hypercholesterolemia / epidemiology
-
Hypertension / epidemiology
-
Infarction, Middle Cerebral Artery / blood
-
Infarction, Middle Cerebral Artery / diagnostic imaging
-
Infarction, Middle Cerebral Artery / drug therapy*
-
Infusions, Intravenous
-
Male
-
Middle Aged
-
Prognosis
-
Recombinant Proteins / administration & dosage
-
Recombinant Proteins / pharmacology
-
Recombinant Proteins / therapeutic use
-
Risk Factors
-
Severity of Illness Index
-
Smoking / epidemiology
-
Thrombolytic Therapy*
-
Tissue Plasminogen Activator / administration & dosage
-
Tissue Plasminogen Activator / pharmacology
-
Tissue Plasminogen Activator / therapeutic use
-
Treatment Outcome
-
Ultrasonography, Doppler, Transcranial
-
Vascular Patency* / drug effects
Substances
-
Blood Glucose
-
Fibrinolytic Agents
-
Recombinant Proteins
-
Tissue Plasminogen Activator